Cue Biopharma, Inc. (CUE) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1241741,
    "name": "Cue Biopharma, Inc.",
    "stock_name": "Cue Biopharma, Inc.",
    "full_name": "Cue Biopharma, Inc.",
    "name_url": "stocks-analysis/cue-biopharma-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "0.55",
    "chg": -0.02,
    "chgp": "-3.17%",
    "dir": -1,
    "prev_price": "0.57",
    "mcapval": "59.71",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US22978P1066",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "386.23 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/cue-biopharma-inc-1241741-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Cue Biopharma, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-cue-biopharma-inc-technically-bullish-or-bearish-3547526",
        "imagepath": "",
        "date": "2025-09-20 19:57:29",
        "description": "As of 3 September 2025, the technical trend for Cue Biopharma, Inc. has changed from sideways to mildly bearish. The current stance is bearish, with key indicators including a bearish daily moving average and a bearish weekly RSI. While the MACD shows mildly bullish signals on both weekly and monthly time frames, the overall sentiment is tempered by bearish readings from Bollinger Bands and a mildly bearish OBV on the weekly chart. \n\nIn terms of performance, Cue Biopharma has underperformed the S&P 500 across multiple periods, with a year-to-date return of -33.02% compared to the S&P 500's 12.22%, and a significant decline of -95.78% over the past five years against the S&P's 96.61% gain...."
      },
      {
        "title": "Is Cue Biopharma, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-cue-biopharma-inc-overvalued-or-undervalued-3543866",
        "imagepath": "",
        "date": "2025-09-20 18:31:08",
        "description": "As of 8 August 2023, Cue Biopharma, Inc. has moved from a grade of does not qualify to risky, indicating a deterioration in its valuation outlook. The company appears to be overvalued given its high Price to Book Value of 7.34, a concerning EV to EBIT of -1.02, and an EV to EBITDA of -1.09, all reflecting significant financial distress. \n\nIn comparison to its peers, Theseus Pharmaceuticals, Inc. has a fair valuation with an EV to EBITDA of 0.3754, while Sangamo Therapeutics, Inc. also carries a risky valuation with an EV to EBITDA of -2.0816. The stark contrast in valuation metrics suggests that Cue Biopharma is not only underperforming relative to its peers but is also facing severe operational challenges. Additionally, Cue Biopharma's stock has underperformed against the S&P 500 across multiple periods, with a year-to-date return of -33.02% compared to the S&P 500's 12.22%, reinforcing the notion that the..."
      }
    ],
    "total": 7,
    "sid": "1241741",
    "stock_news_url": "https://www.marketsmojo.com/news/cue-biopharma-inc-1241741"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Cue Biopharma, Inc. technically bullish or bearish?

2025-09-20 19:57:29

As of 3 September 2025, the technical trend for Cue Biopharma, Inc. has changed from sideways to mildly bearish. The current stance is bearish, with key indicators including a bearish daily moving average and a bearish weekly RSI. While the MACD shows mildly bullish signals on both weekly and monthly time frames, the overall sentiment is tempered by bearish readings from Bollinger Bands and a mildly bearish OBV on the weekly chart. In terms of performance, Cue Biopharma has underperformed the S&P 500 across multiple periods, with a year-to-date return of -33.02% compared to the S&P 500's 12.22%, and a significant decline of -95.78% over the past five years against the S&P's 96.61% gain....

Is Cue Biopharma, Inc. overvalued or undervalued?

2025-09-20 18:31:08

As of 8 August 2023, Cue Biopharma, Inc. has moved from a grade of does not qualify to risky, indicating a deterioration in its valuation outlook. The company appears to be overvalued given its high Price to Book Value of 7.34, a concerning EV to EBIT of -1.02, and an EV to EBITDA of -1.09, all reflecting significant financial distress. In comparison to its peers, Theseus Pharmaceuticals, Inc. has a fair valuation with an EV to EBITDA of 0.3754, while Sangamo Therapeutics, Inc. also carries a risky valuation with an EV to EBITDA of -2.0816. The stark contrast in valuation metrics suggests that Cue Biopharma is not only underperforming relative to its peers but is also facing severe operational challenges. Additionally, Cue Biopharma's stock has underperformed against the S&P 500 across multiple periods, with a year-to-date return of -33.02% compared to the S&P 500's 12.22%, reinforcing the notion that the...

View All News